Wellcome

Nanobiomaterials in drug delivery : applications of nanobiomaterials / edited by Alexandru Mihai Grumezescu.

Contributor(s): Grumezescu, Alexandru Mihai [editor.]Material type: TextTextPublisher: Kidlington, Oxford, UK : William Andrew is an imprint of Elsevier, 2016Description: 1 online resourceContent type: text Media type: computer Carrier type: online resourceISBN: 9780323428668; 0323428665; 9780323428897; 0323428894Subject(s): Nanostructured materials | Nanomedicine | Nanobiotechnology | TECHNOLOGY & ENGINEERING / Engineering (General) | TECHNOLOGY & ENGINEERING / Reference | Nanobiotechnology | Nanomedicine | Nanostructured materialsGenre/Form: Electronic books.DDC classification: 620.1/15 LOC classification: TA418.9.N35Online resources: ScienceDirect
Contents:
Front Cover; Nanobiomaterials in Drug Delivery; Copyright Page; Contents; List of contributors; Preface of the series; Preface; About the Series (Volumes I-XI); About Volume IX; 1 Nanobiomaterials in drug delivery; Abbreviations; 1.1 Introduction; 1.1.1 Parameters of Delivery of Nanoparticles into Biological Systems; 1.1.2 Intratumor Drug Release; 1.1.3 Biological Clearance; 1.1.4 Toxicity of Nanoparticles; 1.2 Preparation and Characterization of Nanomaterials; 1.2.1 Preparation; 1.2.2 Characterization; 1.2.2.1 Physicochemical characterization.
1.3 Nanotechnology-Assisted Formulating of Poorly Water-Soluble Compounds1.4 Biodegradable Polymers Used in Controlled Drug Delivery; 1.5 Multifunctional Nanomaterials for Cancer Therapy; 1.5.1 Targeting; 1.5.2 Imaging; 1.5.3 Chemotherapy; 1.6 Chemical Conjugation of Nanomaterials; 1.6.1 pH-Sensitive Linkages Used for Bioconjugation of Nanomaterials; 1.6.2 Other Chemical Linkages Used for Bioconjugation of Nanomaterials; 1.7 Conclusions; Acknowledgments; References; 2 Dendrimers in drug delivery; 2.1 Introduction; 2.2 Mechanisms of Interaction Between Dendrimers and Drug Molecules.
2.3 Dendrimers as Carriers of Various Types of Drugs2.3.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs); 2.3.2 Anticancer Drugs; 2.3.3 Other Drugs; 2.4 Routes of Administration of Drug-Dendrimers Complexes; 2.4.1 Dendrimers in Intravenous Drug Delivery; 2.4.2 Dendrimers in Oral Drug Delivery; 2.4.3 Dendrimers in Transdermal Drug Delivery; 2.4.4 Dendrimers in Ocular Drug Delivery; 2.4.5 Dendrimers in Pulmonary Drug Delivery; 2.5 Conclusions and Further Prognosis; Acknowledgments; References; 3 Lipid nanoparticles as non-viral vectors for siRNA delivery: concepts and applications.
3.1 Introduction3.2 siRNA: Definition, Mechanism, and Applications; 3.3 Hurdles for siRNA Delivery; 3.4 Strategies to Overcome the Hurdles of siRNA Delivery; 3.4.1 Chemical Modifications in siRNA; 3.4.2 Physical Methods for siRNA Delivery; 3.4.3 Viral Carriers for siRNA Delivery; 3.4.4 Non-viral Carriers for siRNA Delivery; 3.5 Liposomes: The Influence of Charge and Lipid Composition for siRNA Delivery; 3.5.1 Cationic Lipid-Based siRNA Delivery Systems; 3.5.2 Neutral Lipid-Based siRNA Delivery Systems; 3.5.3 Anionic Lipid-Based siRNA Delivery Systems; 3.5.4 Stealth Liposomes.
3.6 Targeted Delivery of siRNA-Loaded Liposomes3.7 Combined Therapy of siRNA-Loaded Liposomes and Conventional Small-Molecule Drugs; 3.8 siRNA-Loaded Liposomes Associated with Physical Methods; 3.9 siRNA-Loaded Liposomes: Clinical Studies; 3.10 Conclusions and Perspectives; References; 4 Nanobiomaterials: Novel nanoplatforms for protein and peptide delivery; 4.1 Introduction; 4.2 Proteins/Peptides as Therapeutics; 4.2.1 Group I-Protein Therapeutics with Enzymatic or Regulatory Activity; 4.2.2 Group II-Protein Therapeutics with Special Targeting Activity; 4.2.3 Group III-Proteinaceous Vaccines.
Tags from this library: No tags from this library for this title. Log in to add tags.
Holdings
Item type Current library Call number Status Date due Barcode
Ebooks Ebooks Mysore University Main Library
Not for loan EBKELV222

Includes bibliographical references and index.

Online resource; title from PDF title page (ScienceDirect, viewed May 9, 2016).

Front Cover; Nanobiomaterials in Drug Delivery; Copyright Page; Contents; List of contributors; Preface of the series; Preface; About the Series (Volumes I-XI); About Volume IX; 1 Nanobiomaterials in drug delivery; Abbreviations; 1.1 Introduction; 1.1.1 Parameters of Delivery of Nanoparticles into Biological Systems; 1.1.2 Intratumor Drug Release; 1.1.3 Biological Clearance; 1.1.4 Toxicity of Nanoparticles; 1.2 Preparation and Characterization of Nanomaterials; 1.2.1 Preparation; 1.2.2 Characterization; 1.2.2.1 Physicochemical characterization.

1.3 Nanotechnology-Assisted Formulating of Poorly Water-Soluble Compounds1.4 Biodegradable Polymers Used in Controlled Drug Delivery; 1.5 Multifunctional Nanomaterials for Cancer Therapy; 1.5.1 Targeting; 1.5.2 Imaging; 1.5.3 Chemotherapy; 1.6 Chemical Conjugation of Nanomaterials; 1.6.1 pH-Sensitive Linkages Used for Bioconjugation of Nanomaterials; 1.6.2 Other Chemical Linkages Used for Bioconjugation of Nanomaterials; 1.7 Conclusions; Acknowledgments; References; 2 Dendrimers in drug delivery; 2.1 Introduction; 2.2 Mechanisms of Interaction Between Dendrimers and Drug Molecules.

2.3 Dendrimers as Carriers of Various Types of Drugs2.3.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs); 2.3.2 Anticancer Drugs; 2.3.3 Other Drugs; 2.4 Routes of Administration of Drug-Dendrimers Complexes; 2.4.1 Dendrimers in Intravenous Drug Delivery; 2.4.2 Dendrimers in Oral Drug Delivery; 2.4.3 Dendrimers in Transdermal Drug Delivery; 2.4.4 Dendrimers in Ocular Drug Delivery; 2.4.5 Dendrimers in Pulmonary Drug Delivery; 2.5 Conclusions and Further Prognosis; Acknowledgments; References; 3 Lipid nanoparticles as non-viral vectors for siRNA delivery: concepts and applications.

3.1 Introduction3.2 siRNA: Definition, Mechanism, and Applications; 3.3 Hurdles for siRNA Delivery; 3.4 Strategies to Overcome the Hurdles of siRNA Delivery; 3.4.1 Chemical Modifications in siRNA; 3.4.2 Physical Methods for siRNA Delivery; 3.4.3 Viral Carriers for siRNA Delivery; 3.4.4 Non-viral Carriers for siRNA Delivery; 3.5 Liposomes: The Influence of Charge and Lipid Composition for siRNA Delivery; 3.5.1 Cationic Lipid-Based siRNA Delivery Systems; 3.5.2 Neutral Lipid-Based siRNA Delivery Systems; 3.5.3 Anionic Lipid-Based siRNA Delivery Systems; 3.5.4 Stealth Liposomes.

3.6 Targeted Delivery of siRNA-Loaded Liposomes3.7 Combined Therapy of siRNA-Loaded Liposomes and Conventional Small-Molecule Drugs; 3.8 siRNA-Loaded Liposomes Associated with Physical Methods; 3.9 siRNA-Loaded Liposomes: Clinical Studies; 3.10 Conclusions and Perspectives; References; 4 Nanobiomaterials: Novel nanoplatforms for protein and peptide delivery; 4.1 Introduction; 4.2 Proteins/Peptides as Therapeutics; 4.2.1 Group I-Protein Therapeutics with Enzymatic or Regulatory Activity; 4.2.2 Group II-Protein Therapeutics with Special Targeting Activity; 4.2.3 Group III-Proteinaceous Vaccines.

There are no comments on this title.

to post a comment.

No. of hits (from 9th Mar 12) :

web counter

Powered by Koha